Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BlaIMP-15 in Pseudomonas aeruginosa in Switzerland

ABSTRACT: First case of IMP-15-producing Pseudomonas aeruginosa in Switzerland

PROVIDER: PRJEB37060 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Project description:IMP-63 producing Pseudomonas aeruginosa and Pseudomonas putida

| PRJNA496031 | ENA

Pseudomonas aeruginosa strain:IMP-13

Project description:Pseudomonas aeruginosa strain:IMP-13 Genome sequencing

| PRJNA507737 | ENA

GNPS_Microcystis aeruginosa

Project description:Metabolic profiles of microcystin and non-microcystin-producing Microcystis aeruginosa strains (Cyanobacteria).

2014-07-09 | MSV000078776 | GNPS

Staphylococcus aureus population structure and genomic profiles in asymptomatic carriers in Switzerland

Project description:genomic profiles of Staphylococcus aureus isolates from asymptomatic carriers in Switzerland

2020-04-08 | E-MTAB-8960 | biostudies-arrayexpress

Cysteamine inhibits glycine utilisation and disrupts virulence in Pseudomonas aeruginosa

Project description:Pseudomonas aeruginosa is a major opportunistic human pathogen which employs a myriad of virulence factors. In people with cystic fibrosis (CF) P. aeruginosa frequently colonises the lungs and becomes a chronic infection that evolves to become less virulent over time, but often adapts to favour persistence in the host with alginate-producing mucoid, slow-growing, and antibiotic resistant phenotypes emerging. Cysteamine is an endogenous aminothiol which has been shown to prevent biofilm formation, reduce phenazine production, and potentiate antibiotic activity against P. aeruginosa, and has been investigated in clinical trials as an adjunct therapy for pulmonary exacerbations of CF. Here we demonstrate (for the first time in a prokaryote) that cysteamine prevents glycine utilisation by P. aeruginosa in common with reported activity blocking the glycine cleavage system in human cells. Despite the inhibition of glycine metabolism, cysteamine inhibits hydrogen cyanide (HCN) production by P. aeruginosa, implicating interference in the regulation of virulence. Cysteamine impaired chemotaxis and reductions in pyocyanin and exopolysaccharide production in cysteamine-treated P. aeruginosa and reduced toxicity of secreted factors in a Galleria mellonella model. Thus, cysteamine has additional potent anti-virulence properties targeting P. aeruginosa, further supporting its therapeutic potential in CF and other infections.

2021-08-19 | PXD027156 | Pride

Pseudomonas aeruginosa

Project description:Pseudomonas aeruginosa clinical case - Genome sequencing and assembly

| PRJNA598709 | ENA

Gammaproteobacteria

Project description:IMP-14-producing P. aeruginosa and K. pneumoniae Genome sequencing

| PRJNA270953 | ENA

VRE ST796 in Switzerland

Project description:Sequencing of VRE in Switzerland, 2018

| PRJEB27159 | ENA

Pseudomonas aeruginosa cystic fibrosis clinical isolates volatile metabolomics

Project description:Untargeted metabolomics analysis of in vitro headspace volatiles from 81 Pseudomonas aeruginosa bacterial isolates from individuals with cystic fibrosis. Headspace volatiles were collected using solid-phase microextraction (SPME) (in triplicate) and comprehensive two-dimensional gas chromatography and time-of-flight mass spectrometry (GCxGC-TOFMS). 15 replicates of un-inoculated media were prepared and analyzed in parallel, for a total of 258 samples.

2020-05-31 | ST001414 | MetabolomicsWorkbench

Shigella sonnei Switzerland

Project description:WGS of selected Shigella sonnei clinical isolates from Switzerland

| PRJEB23646 | ENA